Ana Oaknin

Ana Oaknin, MD, PhD is Head of the Gynecological Malignancies Program at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, one of Spain's premier academic cancer centres and a leading European site for early-phase oncology trials. She is internationally recognized for her pivotal role in the GARNET trial, the single-arm phase I/II study that first established robust clinical activity of dostarlimab — a PD-1 checkpoint inhibitor developed by GlaxoSmithKline/TESARO — in recurrent endometrial and cervical cancers with mismatch repair deficiency or microsatellite instability-high status. As a principal investigator and lead author of the GARNET endometrial cohort data, she contributed to the evidence supporting FDA accelerated approval of dostarlimab for dMMR recurrent endometrial cancer in 2021. Her broader research program encompasses early-phase investigation of antibody-drug conjugates (including mirvetuximab soravtansine, tisotumab vedotin, and upifitamab rilsodotin), immune combination strategies, and novel cell therapy approaches in gynecologic malignancies. Dr. Oaknin is active in ESGO, ENGOT, and GCIG (Gynecologic Cancer InterGroup) trial design committees and has authored over 150 peer-reviewed publications. Her translational research emphasizes characterizing the immune tumor microenvironment in gynecologic cancers and developing predictive biomarkers beyond MMR status.